- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04987892
Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH (IMPACT)
April 24, 2023 updated by: NeoTract, Inc.
Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for Benign Prostatic Hyperplasia
This prospective, multicenter, two-arm, 1:1 randomized controlled trial (RCT) will enroll approximately 250 males at approximately 25 sites located within the United States.
All enrolled subjects will be 45 years of age or older diagnosed with symptomatic benign prostatic hyperplasia (BPH).
They will be randomized to one of two readily available, marketed BPH therapies; Prostatic Urethral Lift procedure with the UroLift System (PUL Arm) or 0.4mg tamsulosin HCl (MED Arm).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This prospective, multicenter, two-arm, 1:1 randomized controlled trial (RCT) will enroll approximately 250 males at approximately 25 sites located within the United States.
All enrolled subjects will be 45 years of age or older diagnosed with symptomatic benign prostatic hyperplasia (BPH).
They will be randomized to one of two readily available, marketed BPH therapies; Prostatic Urethral Lift procedure with the UroLift System (PUL Arm) or 0.4mg tamsulosin HCl (MED Arm).Men 45 or older diagnosed with symptomatic benign prostatic hyperplasia (BPH).
BPH symptoms may range from mild (8) to severe (35) on the IPSS scale.
All enrolled men must meet selection criteria and be candidates for therapy with both UroLift System and 0.4 mg tamsulosin HCl.
Study Type
Interventional
Enrollment (Anticipated)
250
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rogers Mitchell
- Phone Number: 805-403-7107
- Email: rogers.mitchell@neotract.com
Study Locations
-
-
California
-
Pleasanton, California, United States, 94588
- Recruiting
- Neotract
-
Contact:
- Rogers Mitchell
- Phone Number: 925-329-6493
- Email: USPLEClinicalPayments@teleflex.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
43 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Male 45 years of age or older
- Diagnosis of BPH
- Experiencing symptoms of BPH as indicated by an IPSS ≥8 and ≤30
- Willing to wash out of current BPH medication(s), as applicable
- An appropriate candidate for both BPH therapies evaluated in this study.
- Ability to understand and consent to participate in this study
- Willing and able to participate in follow-up evaluations
Exclusion Criteria:
- Use of alpha blocker for BPH unless washed-out for 30 days
- Use of daily phosphodiesterase type 5 inhibitor (PDE5i) for BPH unless washed-out for 30 days
- 5-alpha-reductase inhibitors for BPH used within 6 months of therapy initiation
- Current urinary tract infection or prostatitis
- Current gross hematuria
- Urinary incontinence presumed due to incompetent sphincter
- Catheter-dependent urinary retention within 1 month prior to enrollment
- Prostate volume greater than 100 cc as measured by TRUS
- Prostate specific antigen level of greater than 10 ng/ml within one year of enrollment unless prostate cancer has been ruled out
- History of neurogenic or atonic bladder
- History prostate cancer treatment
- Known to be hypersensitive to tamsulosin HCl or any component of tamsulosin HCl capsules
- Known allergy to nickel, titanium, or stainless steel
- Prior minimally invasive or surgical intervention for BPH
- Urethral conditions that may prevent insertion of delivery system into bladder.
- Currently enrolled in any other investigational clinical research trial that has not completed the primary endpoint
- History of medical, surgical or other conditions that, in the opinion of the investigator, would interfere with the treatment or evaluation of the subject
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Prostatic Lift
Treatment with the UroLift System
|
Prostatic lift
|
Active Comparator: Medication
Treatment with Tamsulosin HCl 0.4mg
|
Tamsulosin HCl 0.4mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Paired comparison of International Prostate Symptom Score (IPSS) percent change
Time Frame: 3 Months after Therapy Initiation
|
The primary study analysis compares the change in BPH symptoms in the PUL Arm to the change in BPH symptoms in the MED Arm measured 3 months after BPH therapy initiation.
This will be measure by International Prostate Symptom Score (IPSS) percent change.
IPSS ranges from 0-35, healthier patients have lower scores than patients more effected by BPH symptoms.
|
3 Months after Therapy Initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Quality of Life (QoL)
Time Frame: 3 months after BPH Therapy Initiation
|
The secondary analysis assesses the change in quality of life (QoL) due to urinary symptoms between the PUL and MED Arms measured 3 months after initiation of BPH therapy.
This will be measured by change in QoL, ranging from 0-6.
Healthier patients have lower scores than patients more effected by BPH symptoms.
|
3 months after BPH Therapy Initiation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Claus Roehrborn, M.D., University of Texas Southwestern Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 6, 2021
Primary Completion (Anticipated)
May 1, 2025
Study Completion (Anticipated)
October 1, 2025
Study Registration Dates
First Submitted
July 9, 2021
First Submitted That Met QC Criteria
July 23, 2021
First Posted (Actual)
August 3, 2021
Study Record Updates
Last Update Posted (Actual)
April 25, 2023
Last Update Submitted That Met QC Criteria
April 24, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP00014
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on BPH
-
Clinical Academic Center (2CA-Braga)Not yet recruiting
-
Assiut UniversityNot yet recruiting
-
Centre hospitalier de l'Université de Montréal...Completed
-
University of North Carolina, Chapel HillBTG International Inc.Completed
-
PROCEPT BioRoboticsUnknownBPHAustralia, Lebanon, United Kingdom, Germany, New Zealand
-
Boston Scientific CorporationTerminatedBPH | BPH With Urinary Obstruction | BPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsUnited States, Australia
-
Yonsei UniversityTerminated
-
National Taiwan University HospitalCompleted
-
Mansoura UniversityRecruiting
-
Sohag UniversityNot yet recruitingBPH | Ejaculatory Dysfunction
Clinical Trials on UroLift System
-
NeoTract, Inc.CompletedBenign Prostatic Hyperplasia | Acute Urinary RetentionUnited Kingdom
-
NeoTract, Inc.CompletedBenign Prostatic Hyperplasia (BPH)
-
NeoTract, Inc.CompletedBenign Prostatic HyperplasiaUnited States, Australia, Canada
-
NeoTract, Inc.Not yet recruitingBenign Prostatic Hyperplasia
-
Royal Marsden NHS Foundation TrustKing's College London; University College, London; Institute of Cancer Research... and other collaboratorsRecruiting
-
NeoTract, Inc.CompletedBenign Prostatic HyperplasiaUnited States
-
Weill Medical College of Cornell UniversityTeleflex; NeoTract, Inc.SuspendedBenign Prostatic HyperplasiaUnited States
-
NeoTract, Inc.CompletedBenign Prostatic HyperplasiaUnited States
-
NeoTract, Inc.CompletedBenign Prostatic HyperplasiaDenmark, United Kingdom, Germany
-
University of Kansas Medical CenterRecruitingBenign Prostatic HyperplasiaUnited States